Background

Sally is a registered nurse/midwife with many years specialist clinical and research experience. In the last decade hepatitis C clinical research trials co-ordination has been her main focus.

She has been involved in the specialist nursing care of marginalised clients with complex needs in both the outreach and hospital clinic settings.

Appointments

• ANMF ( Australian Nursing and Midwifery Federation)
• Australian College of Nursing

Qualifications

• 2003 Immunisation Accreditation Program: Latrobe University, Melbourne
• 1983-1985 Midwifery Certificate: QVMC, Melbourne
• 1983 Paediatric Oncology Certificate: St Bart’s, London, UK
• 1978-1980 General Nurse Certificate: Bethesda/Alfred, Melbourne

Projects (5)

Current (2)

• DARE C: ATAHC II Substudy
  DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
• The Australian Trial in Acute Hepatitis C (ATAHC)
  An NIH-funded multicentre prospective cohort study conducted from 2004-2008 in Australia, featuring 167 subjects.

Past (3)

• ATAHC 2: Australian Trial in Acute Hepatitis C II
  The ATAHC 2 study will examine the effect of interferon with or without Ribavirin in recent HCV infection.
• DAA based therapy for recently acquired hepatitis C – II (DARE-C II)
  To evaluate the combination of SOF plus RBV in patients with recently acquired HCV infection.
• TAP: Treatment and Prevention Hep C study
  Does treating people who inject drugs for their hep C reduce transmission and prevalence?

Publications (2)

2008 (1)

• Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
  Goy K, Von Bibra S, Lewis J, Laurie K, Barr I, Anderson D, Hellard M, Ffrench R
  Influenza Other Respi Viruses. 2008 Jul; 2(4):115-125

2006 (1)

• Acute Hepatitis C treatment Uptake in the Victorian Population.
  Walsh N, Lim M, Nguyen O, Von Bibra S, Dore G, and Hellard M
  18th Annual Conference. 2006 Oct; Abstract page 153

News Articles (1)

2016 (1)

• Hep C: Elimination is the Goal